Decrease of circulating insulin antibodies in two patients treated with continuous subcutaneous infusion of human...

Area of Science:

• Immunology
• Endocrinology
• Metabolic Disorders

Background:

• Patients with insulin-dependent diabetes mellitus (IDDM) can develop circulating insulin antibodies (CIA).
• Previous insulin therapies, including bovine and porcine insulin, were associated with higher antibody formation.
• Continuous subcutaneous insulin infusion (CSII) offers improved glycemic control.

Purpose of the Study:

• To investigate the effect of switching to human insulin delivered via CSII on CIA levels.
• To assess the impact of CSII and human insulin on antibody formation in IDDM patients.

Main Methods:

• Circulating insulin antibodies (CIA) were measured using a kinetic equilibrium assay.
• Serum samples were pretreated to remove free and bound insulin before CIA determination.
• Two patients with IDDM were studied during a transition from animal-sourced insulin to human insulin via CSII.

Main Results:

• A gradual decrease in detectable CIA was observed within 3 weeks of switching to human insulin via CSII.
• A more pronounced reduction in CIA levels was noted 3 months after the switch.
• The study observed a significant reduction in antibody formation post-transition.

Conclusions:

• Human insulin, when administered via CSII, considerably reduces antibody formation in IDDM patients.
• The combination of human insulin and improved metabolic control from CSII is effective in minimizing CIA.
• This suggests a beneficial immunomodulatory effect of human insulin in the context of CSII therapy.